Pre-made Cergutuzumab benchmark antibody ( Whole mAb Fusion, anti-CEACAM5/CD66e therapeutic antibody, Anti-CEA Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-099
Pre-Made Cergutuzumab biosimilar, Whole mAb Fusion, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Cergutuzumab biosimilar, Whole mAb Fusion, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody|
|Format||Whole mAb Fusion|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Solid tumours|